Kurzübersicht für Claudin 19 (CLDN19) (C-Term) Peptid (ABIN975039)
Target
Claudin 19 (CLDN19)
Spezies
Human
Quelle
Synthetic
Applikation
Blocking Peptide (BP), Western Blotting (WB)
Protein Region
C-Term
Produktmerkmale
This is a synthetic peptide designed for use in combination with anti-CLDN19 antibody (Catalog #: ARP33619_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
CLDN19
Reaktivität: Human, Rind (Kuh)
Wirt: Synthetic
BP
Applikationshinweise
Each Investigator should determine their own optimal working dilution for specific applications.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
Konzentration
1 mg/mL
Buffer
Final peptide concentration is 1 mg/mL in PBS.
Handhabung
Avoid repeated freeze-thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
Target
Claudin 19 (CLDN19)
Hintergrund
CLDN19 belongs to the claudin family. It plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. Defects in this gene are the cause of hypomagnesemia renal with ocular involvement (HOMGO). HOMGO is a progressive renal disease characterized by primary renal magnesium wasting with hypomagnesemia, hypercalciuria and nephrocalcinosis associated with severe ocular abnormalities such as bilateral chorioretinal scars, macular colobomata, significant myopia and nystagmus. The product of this gene belongs to the claudin family. It plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. Defects in this gene are the cause of hypomagnesemia renal with ocular involvement (HOMGO). HOMGO is a progressive renal disease characterized by primary renal magnesium wasting with hypomagnesemia, hypercalciuria and nephrocalcinosis associated with severe ocular abnormalities such as bilateral chorioretinal scars, macular colobomata, significant myopia and nystagmus. Two transcript variants encoding distinct isoforms have been identified for this gene.